Structural and functional evidence for testosterone activation of GPRC6A in peripheral tissues

Molecular Endocrinology

Volumn 29, Issue 12, 2015, Pages 1759-1773

  Pi, Min ^a   Kapoor, Karan ^b   Wu, Yunpeng ^a   Ye, Ruisong ^a   Senogles, Susan E ^a   Nishimoto, Satoru K ^a   Hwang, Dong Jin ^a   Miller, Duane D ^a   Narayanan, Ramesh ^a   Smith, Jeremy C ^b,c   Baudry, Jerome ^b,c   Quarles, L D Arryl ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b OAK RIDGE NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR FAMILY C GROUP 6 MEMBER; GLUTAMATE RECEPTOR 5; INSULIN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE; UNCLASSIFIED DRUG; GPRC6A PROTEIN, MOUSE; PROTEIN BINDING;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CONSENSUS SEQUENCE; CONTROLLED STUDY; EMBRYO; GENE MUTATION; HORMONE ACTION; HUMAN; HUMAN CELL; INSULIN RELEASE; ISOMER; LEYDIG CELL; LIGAND BINDING; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECONDARY STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; STEREOSPECIFICITY; TESTOSTERONE SYNTHESIS; TRANSACTIVATION; ANIMAL; CELL LINE; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; BINDING SITES; CELL LINE; HUMANS; MICE; MICE, KNOCKOUT; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TESTOSTERONE;

EID: 84948973471     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2015-1161     Document Type: Article

References (67)

1. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009; 12(3):232-240.
2. Asuthkar S, Demirkhanyan L, Sun X, et al. The TRPM8 protein is a testosterone receptor: II. Functional evidence for an ionotropic effect of testosterone onTRPM8. J Biol Chem. 2015;290(5):2670-2688.
3. Benten WP, Lieberherr M, Stamm O, Wrehlke C, Guo Z, Wunderlich F. Testosterone signaling through internalizable surface receptors in androgen receptor-free macrophages. Mol Biol Cell. 1999; 10(10):3113-3123.
4. Karsenty G, Oury F. Regulation of male fertility by the bone-derived hormone osteocalcin. Mol Cell Endocrinol. 2014;382(1): 521-526.
5. Oury F, Khrimian L, Denny CA, et al. Maternal and offspring pools of osteocalcin influence brain development and functions. Cell. 2013;155(1):228-241.
6. Wellendorph P, Bräuner-Osborne H. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-pro-tein-coupled receptor. Gene. 2004;335:37-46.
7. Wei J, Hanna T, Suda N, Karsenty G, Ducy P. Osteocalcin promotes ß-cell proliferation during development and adulthood through Gprc6a. Diabetes. 2014;63(3):1021-1031.
8. Pi M, Faber P, Ekema G, et al. Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem. 2005; 280(48):40201-40209.
9. Fulzele K, Riddle RC, DiGirolamo DJ, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142(2):309-319.
10. Ferron M, Wei J, Yoshizawa T, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010; 142(2):296-308.
11. Oury F, Sumara G, Sumara O, et al. Endocrine regulation of male fertility by the skeleton. Cell. 2011;144(5):796-809.
12. Pi M, Chen L, Huang MZ, et al. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One. 2008; 3(12):e3858.
13. Pi M, Wu Y, Quarles LD. GPRC6A mediates responses to osteocalcin in ß-cells in vitro and pancreas in vivo. J Bone Miner Res. 2011;26(7):1680-1683.
14. Lanzino M, Sisci D, Morelli C, et al. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells-identification of a novel androgen response element. Nucleic Acids Res. 2010;38(16): 5351-5365.
15. Pi M, Parrill AL, Quarles LD. GPRC6A mediates the non-genomic effects of steroids. J Biol Chem. 2010;285(51):39953-39964.
16. Ko E, Choi H, Kim B, et al. Testosterone stimulates Duox1 activity through GPRC6A in skin keratinocytes. J Biol Chem. 2014; 289(42):28835-28845.
17. Pi M, Quarles LD. Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. Endocrinology. 2012;153(5):2062-2069.
18. Pi M, Zhang L, Lei SF, et al. Impaired osteoblast function in GPRC6A null mice. J Bone Miner Res. 2010;25(5):1092-1102.
19. Tsuka S, Aonuma F, Higashi S, et al. Promotion of insulin-induced glucose uptake in C2C12 myotubes by osteocalcin. Biochem Bio-phys Res Commun. 2015;459(3):437-442.
20. Jacobsen SE, Norskov-Lauritsen L, Thomsen AR, et al. Delineation of the GPRC6A receptor signaling pathways using a mammalian cell line stably expressing the receptor. J Pharmacol Exp Ther. 2013;347(2):298-309.
21. Kuang D, Yao Y, Lam J, Tsushima RG, Hampson DR. Cloning and characterization of a family C orphan G-protein coupled receptor. J Neurochem. 2005;93(2):383-391.
22. Liu M, Shapiro ME. A new method for isolation of murine islets with markedly improved yields. Transplant Proc. 1995;27(6): 3208-3210.
23. Gerling IC, Serreze DV, Christianson SW, Leiter EH. Intrathymic islet cell transplantation reduces ß-cell autoimmunity and prevents diabetes in NOD/Lt mice. Diabetes. 1992;41(12):1672-1676.
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
25. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013;30(4):772-780.
26. MacKerell AD, Bashford D, Bellott M, et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. JPhys Chem B. 1998;102(18):3586-3616.
27. Kall L, Krogh A, Sonnhammer EL. An HMM posterior decoder for sequence feature prediction that includes homology information. Bioinformatics. 2005;21(suppl 1):i251-i257.
28. Labute P. The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem. 2008; 29(10):1693-1698.
29. Wu H, Wang C, Gregory KJ, et al. Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science. 2014;344(6179):58-64.
30. Doré AS, Okrasa K, Patel JC, et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature. 2014;511(7511):557-562.
31. Xiao YC, Hardy DO, Sottas CM, Li XK, Ge RS. Inhibition of LH-stimulated androgen production in rat immature Leydig cells: effects on nuclear receptor steroidogenic factor 1 by FGF2. Growth Factors. 2010;28(1):1-9.
32. Christiansen B, Hansen KB, Wellendorph P, Bräuner-Osborne H. Pharmacological characterization of mouse GPRC6A, an L-a-ami-no-acid receptor modulated by divalent cations. Br J Pharmacol. 2007;150(6):798-807.
33. Sabek OM, Nishimoto SK, Fraga D, Tejpal N, Ricordi C, Gaber AO. Osteocalcin effect on human ß-cells mass and function. Endocrinology. 2015;156(9):3137-3146.
34. Clemmensen C, Smajilovic S, Wellendorph P, Brauner-Osborne H. The G protein-coupled receptor, class C, group 6, subtype A (GPRC6A) receptor: from cloning to physiological function. Br J Pharmacol. 2013;171(5):1129-1141.
35. Faure H, Gorojankina T, Rice N, et al. Molecular determinants of non-competitive antagonist binding to the mouse GPRC6A receptor. Cell Calcium. 2009;46(5-6):323-332.
36. Pi M, Quarles LD. GPRC6A regulates prostate cancer progression. Prostate. 2012;72(4):399-409.
37. Dreaden EC, Gryder BE, Austin LA, et al. Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjug Chem. 2012; 23(8):1507-1512.
38. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 1990;50(17):5382-5386.
39. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and-independent glucose-stimulated insulin secretion. Diabetes. 2000;49(3):424-430.
40. Bohl CE, Wu Z, Chen J, et al. Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bioorg Med Chem Lett. 2008;18(20):5567-5570.
41. Chen J, Hwang DJ, Bohl CE, Miller DD, Dalton JT. A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther. 2005;312(2):546-553.
42. Chen J, Hwang DJ, Chung K, et al. In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Endocrinology. 2005;146(12): 5444-5454.
43. Hwang DJ, Yang J, Xu H, et al. Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorg Med Chem. 2006;14(19):6525-6538.
44. Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology. 2009;150(1):385-395.
45. Jones A, Hwang DJ, Duke CB 3rd, et al. Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther. 2010;334(2):439-448.
46. Jones A, Hwang DJ, Narayanan R, Miller DD, Dalton JT. Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology. 2010;151(8):3706-3719.
47. Kim J, Wu D, Hwang DJ, Miller DD, Dalton JT. The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluo-romethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther. 2005;315(1):230-239.
48. Li W, Hwang DJ, Cremer D, et al. Structure determination of chiral sulfoxide in diastereomeric bicalutamide derivatives. Chirality. 2009;21(6):578-583.
49. Mohler ML, Bohl CE, Jones A, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. JMed Chem. 2009;52(12):3597-3617.
50. Mohler MLN, Vipin A, Hwang DJ, et al. Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates. Expert Opin Ther Pat. 2005;15(11):1565-1585.
51. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrmol. 2008;22(11):2448-2465.
52. Narayanan R, Ahn S, Cheney MD, et al. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One. 2014;9(7):e103202.
53. Gloriam DE, Wellendorph P, Johansen LD, et al. Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor. Chem Biol. 2011;18(11):1489-1498.
54. Silve C, Petrel C, Leroy C, et al. Delineating a Ca2 + binding pocket within the venus flytrap module of the human calcium-sensing receptor. J Biol Chem. 2005;280(45):37917-37923.
55. Ellingson SR, Miao Y, Baudry JY, Smith JC. Multi-conformer ensemble docking to difficult protein targets. J Phys Chem B. 2014; 119(3):1026-1034.
56. Meier JJ, Butler AE, Saisho Y, et al. ß-Cell replication is the primary mechanism subserving the postnatal expansion of ß-cell mass in humans. Diabetes. 2008;57(6):1584-1594.
57. Hanchang W, Semprasert N, Limjindaporn T, Yenchitsomanus PT, Kooptiwut S. Testosterone protects against glucotoxicity-induced apoptosis of pancreatic ß-cells (INS-1) and male mouse pancreatic islets. Endocrinology. 2013;154(11):4058-4067.
58. Host C, Gormsen LC, Hougaard DM, Christiansen JS, Pedersen SB, Gravholt CH. Acute and short-term chronic testosterone fluctuation effects on glucose homeostasis, insulin sensitivity, and adi-ponectin: a randomized, double-blind, placebo-controlled, crossover study. J Clin Endocrinol Metab. 2014;99(6):E1088-E1096.
59. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009;5(12):673-681.
60. Boonyaratanakornkit V, Edwards DP. Receptor mechanisms mediating non-genomic actions of sex steroids. Semin Reprod Med. 2007;25(3):139-153.
61. Bukulmez O, Hardy DB, Carr BR, et al. Androstenedione up-regulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis. J Clin Endocrinol Metab. 2008;93(9):3471-3477.
62. Loss ES, Jacobus AP, Wassermann GF. Rapid signaling responses in Sertoli cell membranes induced by follicle stimulating hormone and testosterone: calcium inflow and electrophysiological changes. Life Sci. 2011;89(15-16):577-583.
63. Sharpe RM. Intratesticular regulation of testosterone secretion: comparison of the effects and interactions of hCG, an LHRH agonist and testicular interstitial fluid on Leydig cell testosterone secretion in vitro. Mol Cell Endocrinol. 1985;41(2-3):247-255.
64. O’Hara L, McInnes K, Simitsidellis I, et al. Autocrine androgen action is essential for Leydig cell maturation and function, and protects against late-onset Leydig cell apoptosis in both mice and men. FASEB J. 2015;29(3):894-910.
65. Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementation with and without a dual 5a-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA. 2012;307(9):931-939.
66. Takata R, Akamatsu S, Kubo M, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010;42(9):751-754.
67. Bhindi B, Locke J, Alibhai SM, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2014;67(1):64-70.